19:32 , Dec 14, 2018 |  BC Week In Review  |  Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Dec. 12 that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was...
23:34 , Dec 13, 2018 |  BC Extra  |  Company News

Biogen returns gene therapies to AGTC on lack of clinical activity

Applied Genetic Technologies Corp. (NASDAQ:AGTC) said late Wednesday that Biogen Inc. (NASDAQ:BIIB) terminated the companies’ gene therapy collaboration, leaving behind a partnership originally established to help Biogen build its gene therapy expertise. AGTC was down...
01:46 , May 5, 2018 |  BioCentury  |  Product Development

Rebuilding Biogen’s brain

Biogen Inc. is still a long way from a full rebuild of its pipeline, with an Alzheimer’s disease-laden Phase III lineup that needs to diversify. But there’s progress in the early- to mid-stage programs where...
18:32 , Mar 8, 2017 |  BC Innovations  |  Distillery Techniques

Drug delivery; drug platforms

TECHNOLOGY: Viral vectors; gene therapy A Cas9 ortholog derived from Campylobacter jejuni could enable the use of AAV vectors to deliver CRISPR-based gene therapies. The 984-residue C. jejuni ortholog is smaller than the Cas9 enzymes...
00:16 , Jan 12, 2017 |  BC Extra  |  Company News

FDA reviewing Herceptin biosimilar from Mylan, Biocon

Mylan N.V. (NASDAQ:MYL) and Biocon Ltd. (NSE:BIOCON; BSE:BIOCON) said FDA accepted for review a BLA for Myl-1401O , their proposed biosimilar of Herceptin trastuzumab to treat HER2-positive breast cancer. The BsUFA date is Sept. 3....
07:00 , Sep 19, 2016 |  BC Week In Review  |  Clinical News

XLRS: Phase I/II data

Top-line data from 8 patients with XLRS in an open-label, U.S. Phase I/II trial showed that low- and mid-dose XLRS were generally well tolerated with mild to moderate ocular inflammation reported in the “majority” of...
07:00 , Sep 13, 2016 |  BC Extra  |  Clinical News

Applied Genetic slides after clinical updates

Applied Genetic Technologies Corp. (NASDAQ:AGTC) fell $4.19 (32%) to $9 on Tuesday after it said enrollment was slower than expected in two Phase I/II studies of its ocular gene therapy candidates. One of the studies...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Biogen, Applied Genetic Technologies preclinical data

In retinoschisis X-linked juvenile 1 ( RS1 ; XLRS1 )-deficient mice, intravitreal rAAV2tYF-CB-hRS1 was well tolerated with no test article-related changes in ophthalmic examinations. AGTC said there was minimal to slight mononuclear cell infiltrates in...
07:00 , Jul 27, 2015 |  BioCentury  |  Strategy

Rules of competition

Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where - even in Orphan diseases - a better product can steal market share. The reason is that...
07:00 , Jun 15, 2015 |  BC Week In Review  |  Financial News

Fulcrum Venture India financial update

Fulcrum Venture India , Chennai, India   Business: Finance   Date announced: 2015-06-10   Note: Fulcrum Venture India announced the final close of its second fund, Fulcrum Venture India Fund II, at Rs1 billion ($15.6...